Edit

Interleukin Genetics

http://www.ilgenetics.com/

Last activity: 03.07.2021

Probably Closed

Categories: HealthTechManagementMarketPersonalProductWellness

Genetics-based personalized health company that develops genetic tests for use in the emerging personalized health market.

Mentions

Total raised: $12M

Investors 2

Date	Name	Website
03.07.2021	New Enterp...	nea.com
-	Bay City C...	baycitycap...

Funding Rounds 1

Date	Series	Amount	Investors
20.05.2013	-	$12M	-

Mentions in press and media 22

Date	Title	Description
04.08.2017	Learning from failure: What Theranos, Interleukin Genetics, & Courtagen can teach us about IVDs	Developing and commercializing an in vitro diagnostic (IVD) is a complex enterprise involving numerous tasks accomplished by a variety of specialized and knowledgeable individuals. Generally, the process can be broken down into product conc...
03.11.2016	Interleukin Genetics Launches The ILUSTRA™ Inflammation Management Program	Waltham, MA — Interleukin Genetics, Inc. (OTCQB:ILIU) a life science company focused on the genetics of chronic inflammation, today unveiled the ILUSTRA™ Inflammation Management Program. The program targets individuals at elevated risk for ...
03.08.2016	Interleukin Genetics Strengthens Commercial Leadership with Key Appointments	Waltham, MA — Interleukin Genetics, Inc. (OTCQB: ILIU), a life science company focused on the genetics of chronic inflammation, today announced the appointment of two senior leaders to enhance its commercial team and capabilities. Stephan T...
01.08.2016	Interleuken Genetics Announces $5.6M Financing	Waltham, MA — Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, announced today that it has entered into an ag...
12.07.2016	Interleukin Genetics To Offer Inflammation Management Program To Amway Employees	Waltham, MA — Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on the genetics of chronic inflammation announced today that it has signed an agreement with Amway, a leading direct selling company, to provide Interle...
26.04.2016	Interleukin Genetics Receives Notice of Allowance for US Patent for PerioPredict Genetic Risk Test	Waltham, MA — Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced that it has received a notice ...
21.04.2016	Interleuken’s PerioPredict Genetic Risk Test Incorporated into Freedom Dental Plan	Waltham, MA — Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced it has signed an agreement wit...
05.04.2016	Interleukin Genetics Announces Clarification of Commercial Test Compliance	Waltham, MA — Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced the results of discussions wit...
29.03.2016	Interleukin Genetics Announces Study to Evaluate Impact of PerioPredict on Patient Engagement and Preventive Care	Waltham, MA — Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced Institutional Review Board (IR...
17.03.2016	Interleukin Genetics Appoints Global Clinical Advisory Board	Waltham, MA — Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases that reduce longevity and life quality, today announced the appointment of le...
15.04.2015	Interleukin Genetics Granted Key European Patent	Waltham, MA — Interleukin Genetics, Inc. (OTCQB:ILIU) today announced that it has been granted a patent by the European Patent Office (EPO) covering the Company’s Inherent Health® Weight Management Genetic Test. The granted patent, entitled...
07.04.2015	Interleukin Genetics Appoints Mark B. Carbeau as CEO	Waltham, MA – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced the appointment of Mark B. Carbeau as Chief Executive Officer and Director. Dr. Kenneth S. Kornman, DDS, PhD, who served as the President and CEO since August 2012, will...
01.04.2015	Interleukin Genetics Collaborators Present Research at the 2015 Experimental Biology Annual Meeting	Waltham, MA — Interleukin Genetics, Inc. (OTCQB: ILIU) today announced two late-breaking poster presentations supporting its Inherent Health® Weight Management Genetic Test at the 2015 Experimental Biology Annual Meeting taking place March ...
05.01.2015	Interleukin’s PerioPredict® Genetic Test Featured in Genome Magazine	Waltham, MA — Interleukin Genetics, Inc. (OTCQB: ILIU) today announced that an article, titled “Dentistry Gets Personalized,” has been published online in Genome magazine. The article, which also appeared in the Fall 2014 print issue, inclu...
13.10.2014	Interleukin’s PerioPredict® Receives 2014 DrBicuspid Dental Excellence Award	Waltham, MA — Interleukin Genetics, Inc. (ILIU) announced today it received the 2014 DrBicuspid Dental Excellence Award for PerioPredict®, the Company’s commercially available genetic risk test for periodontal disease. PerioPredict® was rec...
22.04.2014	Interleukin Genetics Secures Approval in New York State to Offer PerioPredict™	WALTHAM, Mass.–(BUSINESS WIRE)–April 22, 2014– Interleukin Genetics, Inc. (OTCQB:ILIU) today announced it has received conditional approval from the New York State Department of Health to offer, process and report the results of the PerioPr...
20.05.2013	Interleukin Genetics Announces $12 Million Private Placement	WALTHAM, Mass. – May 20, 2013 – Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it has raised $12.0 million in gross proceeds through a private placement of its securities to accredited investors. Interleukin sold an aggregate...
15.11.2010	Clinical trials roundup: Medtronic study to boost CRT-D industry?	Cardiac resynchronization-therapy defibrillators reduced the mortality rate by 29 percent in patients with mild symptoms of heart failure, according to a study released by Medtronic Inc. (NYSE:MDT) at the annual meeting of the American Hear...
30.04.2010	Interleukin adds VC vet to board	Interleukin Genetics Inc. (NYSE:ILI) named a venture capital veteran, William Mills III, to its board of directors. Mills will replace the Waltham, Mass.-based company’s founder, president and chief scientific officer Ken Kornman if shareho...
05.03.2010	Interleukin raises $5 million	Interleukin Genetics Inc. (NYSE:ILI) drummed up about $5.3 million in commitments from institutional investors in a registered direct offering. The Waltham, Mass.-based genetic test maker said it expects to pull in $4.9 million after deduct...
02.03.2010	Interleukin named in patent suit by Australian genetic testing firm	Interleukin Genetics Inc. (NYSE:ILI) and seven other firms were named in a patent infringement lawsuit filed by an Australian genetic testing company. Genetic Technologies Ltd. of Victoria, Australia, asserts that Interleukin is one of eigh...
-	Learning from failure: What Theranos, Interleukin Genetics, & Courtagen can teach us about IVDs	In the aftermath of the Theranos downfall, dozens of pundits have performed virtual autopsies of where CEO Elizabeth Holmes went wrong, generally highlighting a lack of full disclosure about the technology its labs were using. In the beginn...

Interleukin Genetics

Investors 2

Funding Rounds 1

Mentions in press and media 22

Reviews 0